Sleep and Stress Peptides

No source behind this page shows that it is. FDA's Pharmacy Compounding Advisory Committee reviewed DSIP, which FDA calls emideltide, on July 24, 2026, for opioid withdrawal, chronic insomnia and narcolepsy.¹ Trade press reported that the committee voted 7 to 6, with 1 abstention, against adding it to the 503A bulks list, the only one of the seven peptides reviewed that month to be turned down.² That vote was about pharmacy compounding, not a verdict on the sleep research, which the DSIP education page reviews.

Its safety in people has not been established: FDA says it has not identified safety information on emideltide (DSIP) for the proposed route, so it lacks enough information to know whether the drug would cause harm in people.³ FDA also lists DSIP among substances once in Category 2, its group for significant safety concerns, whose nominations were withdrawn.³ Health Canada's April 2026 warning about injectable peptides bought online named DSIP and said such products can lead to infections and allergic reactions.⁴

Selank is in this category, and the Selank product page lists its strengths, price and stock. Before ordering, note its regulatory record. FDA's safety-risk page lists selank acetate among withdrawn Category 2 nominations, flags a possible risk of immune reactions for some routes, and says it lacks important information on any safety issues when selank acetate is given to people.³ Semax is also sold here, outside the categories, and the Selank education page covers the published studies.